Docetaxel/Capecitabine
PreclinicalSmall molecule
Docetaxel/Capecitabine is one of 3 small molecule programs targeting Cancer of the Esophagus. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Cancer of the Esophagus
#DrugCompanyPhaseTrials
1Modified FOLFOX6
AmgenPreclinical
Docetaxel/Capecitabine
GGeorgia Center for Oncology Research & Education
Preclinical
Cisplatin/docetaxel
GGeorgetown University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Breast Cancer1 trial
Gastric Cancer1 trial
A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
Terminated·—·Phase 2·NCT01967875·27 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Docetaxel/Capecitabine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details